Results 41 to 50 of about 123,264 (354)

Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the identification of novel targets and development of effective treatment strategies are urgently needed to improve patient outcomes.
Olson, Michael F., Pajic, Marina, Rath, Nicola, Timpson, Paul, Vennin, Claire   +4 more
core   +1 more source

Effect of miR-184 on Proliferation and Apoptosis of Pancreatic Ductal Adenocarcinoma and Its Mechanism

Technology in Cancer Research & Treatment, 2020
Objective: Previous studies have shown that abnormal expression of microRNA-184 leads to a variety of cancers, including pancreatic ductal adenocarcinoma, suggesting microRNA-184 as a new treatment target for pancreatic ductal adenocarcinoma.
Shentao Li MBBS, He Li MD, PhD, Weiwei Ge PhD, Kai Song MM, Chunyu Yuan MM, Ran Yin MBBS   +5 more
doaj   +1 more source

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma. [PDF]

PLoS ONE, 2016
BACKGROUND:Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic ...
Michael Tayao, Juliana Andrici, Mahtab Farzin, Adele Clarkson, Loretta Sioson, Nicole Watson, Terence C Chua, Tamara Sztynda, Jaswinder S Samra, Anthony J Gill   +9 more
doaj   +1 more source

Clinical and molecular characterization of HER2 amplified-pancreatic cancer [PDF]

, 2013
<p>Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome ...
Biankin, A.V., Chang, D.K., Chantrill, L., Chin, V., Chou, A., Cowley, M.J., Gill, A.J., Goldstein, D., Grimmond, S.M., Humphris, J., Johns, A.L., Kassahn, K.S., Mead, R., Miller, D.K., Morey, A.L., Musgrove, E.A., Nagrial, A.M., Nones, K., Pajic, M., Patch, A.M., Pearson, J.V., Pinese, M., Rooman, I., Samra, J.S., Toon, C.W., Waddell, N., Wasan, H., Wu, J.   +27 more
core   +3 more sources

Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression [PDF]

, 2017
Gastrointestinal cancer is a group of tumors that affect multiple sites of the digestive system, including the stomach, liver, colon and pancreas. These cancers are very aggressive and rapidly metastasize, thus identifying effective targets is crucial ...
Bacigalupo, Maria Lorena, Carabias, Pablo, Troncoso, María Fernanda   +2 more
core   +1 more source

Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial–mesenchymal transition

Tumor Biology, 2017
Pancreatic ductal adenocarcinoma is one of the most lethal cancers. The Hippo pathway is involved in tumorigenesis and remodeling of tumor microenvironments.
Honglong Wei, Zongzhen Xu, Feng Liu, Fuhai Wang, Xin Wang, Xueying Sun, Jie Li   +6 more
doaj   +1 more source

ROCK signalling induced gene expression changes in mouse pancreatic ductal adenocarcinoma cells [PDF]

, 2016
The RhoA and RhoC GTPases act via the ROCK1 and ROCK2 kinases to promote actomyosin contraction, resulting in directly induced changes in cytoskeleton structures and altered gene transcription via several possible indirect routes.
Clark, William, Kalna, Gabriela, Olson, Michael F., Rath, Nicola   +3 more
core   +1 more source

Targeting mTOR in Pancreatic Ductal Adenocarcinoma [PDF]

Frontiers in Oncology, 2016
Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data have shown that inhibition of mammalian target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition ...
Sentia eIriana, Shahzad eAhmed, Jun eGong, Jun eGong, Alagappan Anand Annamalai, Richard eTuli, Andrew Eugene Hendifar   +6 more
openaire   +6 more sources

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis [PDF]

Case Reports in Gastroenterology, 2011
Autoimmune pancreatitis (AIP), in contrast to other benign chronic pancreatic diseases, can be cured with immunosuppressant drugs, thus the differentiation of AIP from pancreatic cancer is of particular interest in clinical practice. There is the possibility that some patients with AIP may develop pancreatic cancer, and this possibility contributes to ...
Pezzilli R, Vecchiarelli S, Di Marco MC, Serra C, SANTINI, DAVIDE, Calculli L, FABBRI, DARIO, Rojas Mena B, Imbrogno A, Source Pancreas Unit Department of Digestive Diseases and Internal Medicine University of Bologna Bologna Italy.   +9 more
openaire   +4 more sources

Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer: Potential Target for New Therapeutic Approach? [PDF]

, 2015
Fibroblast growth factors and their receptors play a key role in cell proliferation, migration and differentiation. Fibroblast growth factor receptor 2 (FGFR2) is involved in carcinogenesis and its altered expression has been shown in several tumors ...
Angeloni, Antonio, Ceccarelli, Simona, Vescarelli, Enrica   +2 more
core   +1 more source